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Background/introduction
Objectives: To evaluated the efficacy of Focal One
device for focal treatment of localized prostate cancer.
Methods
Material and method: Focal One® is a device designed
for the focal therapy of Prostate Cancer combing the
necessary tools to visualize, target, treat and validate the
focal treatment. MR volumes are imported through the
hospital’s network. The operator defines the contours of
the prostate and the regions of interests that have been
confirmed as prostate tumors. The same contouring of
the prostate is performed on the live ultrasound volume
acquired by the transrectal probe. The software pro-
ceeds to an “elastic fusion”: the live Ultrasound volume
is considered as the reference volume and the MR
volume is smoothly deformed so the 3D contour of the
prostate on the MR volume matches perfectly the con-
tours of the prostate on the Ultrasound Volume. The
same 3D elastic transformation is applied to the ROIs
initially indicated on the MR image so they appear at
the adequate position on the live Ultrasound Image,
guiding the planning process. The Focal One is
equipped with a new generation of HIFU probe able to
electronically vary the focal point along the acoustic axis
using a HIFU multi-element phase array transducer.
During the HIFU energy delivery process, the operator
sees a live ultrasound image of what is being treated
and, if necessary, can readjust the treatment planning.
At the end of the treatment process, a Contrast-
enhanced Ultrasound volume is acquired showing the
de-vascularized areas.
Teen patients with mono focal prostate cancer were
treated between March 2013 and January 2014. HIFU
treatment process was realized with the Focal One
device using a 6 mm safety margin around the tumor.
Contrast enhanced MRI is performed at day 2 after
HIFU and Control biopsies guided with contrast-
enhanced Ultrasound imaging were achieved one month
after HIFU inside and in the rime of the treated area.
Results and conclusions
Results: The mean age of patients was 65.8±5.5 years.
The Clinical stage was T1 for 9 patients and T2a for
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Figure 1 MRI registration with elastic fusion.
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1 patient. The Gleason sum was 6 for 7 patients and 7(3
+4) for 3 patients. The PSA value was 4.47± 3.7 ng/ml
and the mean Prostate Volume was 50±23 cc. The
mean treated volume was 14 cc (7.3-20.4) 28% of pros-
tate gland. The mean nadir PSA value was 3.46±2 ng/
ml. In all patients, targeted biopsies inside the treated
area performed day 30 after the HIFU session demon-
strated a complete destruction of the targeted tumor.
No incontinence was observed. A partial loss of potency
(IIEF <17) occurred in 2 patients.
Conclusions: Focal One device is able to achieve a
complete destruction of small prostate cancer using an
elastic magnetic resonance-ultrasound (MR-US) registra-
tion system for tumor location and HIFU treatment
planning. Multicenter trial is in progress (30 patients).
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Figure 2 Contrast-enhanced Ultrasound showing the de-
vascularized areas.
Figure 3 Control MRI after focal HIFU
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